These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 21029610

  • 1. [Clinical study on combination of multiple regimens in treatment of osteoporosis in perimenopause and postmenopausal women].
    Guan YT, Cai LL, Ding HX, Chen GD, Hu Y.
    Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):571-4. PubMed ID: 21029610
    [Abstract] [Full Text] [Related]

  • 2. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
    Ringe JD, Farahmand P, Schacht E, Rozehnal A.
    Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 7. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
    Reginster JY, Lecart MP, Richy F.
    J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
    [Abstract] [Full Text] [Related]

  • 8. "Twice-a-month" clodronate 200 mg IM: a new dosing regimen and improved therapy adherence in the treatment of postmenopausal osteoporosis.
    Muratore M, Quarta L, Calcagnile F, Quarta E.
    Adv Ther; 2010 May; 27(5):314-20. PubMed ID: 20526703
    [Abstract] [Full Text] [Related]

  • 9. Relationship between increased endogenous parathormone levels and bone density in postmenopausal women treated with bisphosphonates.
    Coin A, Veronese N, Bolzetta F, De Rui M, Manzato E, Sergi G.
    Panminerva Med; 2012 Dec; 54(4):277-82. PubMed ID: 23123579
    [Abstract] [Full Text] [Related]

  • 10. Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study.
    Rhee Y, Kang M, Min Y, Byun D, Chung Y, Ahn C, Baek K, Mok J, Kim D, Kim D, Kim H, Kim Y, Myoung S, Kim D, Lim SK.
    Osteoporos Int; 2006 Dec; 17(12):1801-7. PubMed ID: 17019520
    [Abstract] [Full Text] [Related]

  • 11. Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate.
    Panico A, Lupoli GA, Fonderico F, Marciello F, Martinelli A, Assante R, Lupoli G.
    Thyroid; 2009 May; 19(5):437-42. PubMed ID: 19415993
    [Abstract] [Full Text] [Related]

  • 12. Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis.
    Nuti R, Bianchi G, Brandi ML, Caudarella R, D'Erasmo E, Fiore C, Isaia GC, Luisetto G, Muratore M, Oriente P, Ortolani S.
    Rheumatol Int; 2006 Mar; 26(5):445-53. PubMed ID: 16283320
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment.
    Iba K, Sonoda T, Takada J, Dohke T, Yamashita T.
    J Bone Miner Metab; 2017 Mar; 35(2):171-176. PubMed ID: 26832388
    [Abstract] [Full Text] [Related]

  • 16. Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass.
    Felsenberg D, Bock O, Börst H, Armbrecht G, Beller G, Degner C, Stephan-Oelkers M, Schacht E, Mazor Z, Hashimoto J, Roth HJ, Martus P, Runge M.
    J Musculoskelet Neuronal Interact; 2011 Mar; 11(1):34-45. PubMed ID: 21364273
    [Abstract] [Full Text] [Related]

  • 17. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [Abstract] [Full Text] [Related]

  • 18. Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia.
    Gorai I, Hattori S, Tanaka Y, Iwaoki Y.
    J Bone Miner Metab; 2012 May; 30(3):349-58. PubMed ID: 22130786
    [Abstract] [Full Text] [Related]

  • 19. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
    Ringe JD, Faber H, Fahramand P, Schacht E.
    J Rheumatol Suppl; 2005 Sep; 76():33-40. PubMed ID: 16142849
    [Abstract] [Full Text] [Related]

  • 20. [Bone alkaline phosphatase and N-MID osteocalcin in monitoring of osteoporosis treatment with recombinant human parathyroid hormone 1-34].
    Weng XM, Pan JP.
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 42(5):578-82. PubMed ID: 24167142
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.